BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Actavis 

Morris Corporate Center III
400 Interpace Parkway
Parippany  New Jersey  07054  U.S.A.
Phone: 1-862-261-7000 Fax: n/a


SEARCH JOBS

View Clinical Trials from BioPharm Insight


Actavis, Inc. (NYSE: ACT) is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. The Company has global and U.S. headquarters in Parsippany, New Jersey, USA, and international headquarters in Zug, Switzerland.

Actavis is the world’s third-largest generics prescription drug manufacturer, with more than 750 products marketed globally through operations in more than 60 countries. Actavis’ global branded pharmaceutical business develops and markets products principally in Urology and Women’s Health, and is committed to developing and marketing biosimilars products in Women’s Health, Oncology and other therapeutic categories. In addition, Actavis is the fourth-largest U.S. generic pharmaceutical product distributor through its Anda, Inc. business, and also develops and out-licenses generic pharmaceutical products outside of the U.S. through its Medis third-party business.

"Twice As" Video

"Our Winning Way" Video


 Key Statistics


Email: actavis@actavis.com
Ownership: Public

Web Site: Actavis
Employees:
Symbol: ACT
 



Industry
Pharmaceutical






 Company News
Actavis (ACT) Receives U.S. FDA Approval For AVYCAZ (CEFTAZIDIME-AVIBACTAM) 2/26/2015 6:48:51 AM
Actavis (ACT) Confirms Generic Uceris Patent Challenge 2/25/2015 7:15:03 AM
Actavis (ACT) Announces Pricing Of Public Offerings Of Ordinary Shares And Mandatory Convertible Preferred Shares In Connection With Pending Acquisition Of Allergan (AGN) 2/25/2015 6:53:14 AM
Actavis (ACT) Receives Final Approval For Generic Version Of Subutex 2/20/2015 10:41:14 AM
Actavis (ACT) Not Done, Still Eyes "Couple Billion Dollar" Deals to Fill Pipeline 2/19/2015 6:50:10 AM
Actavis (ACT) Non-GAAP Net Revenue Increases 44% To $4 Billion In Fourth Quarter 2014; Non-GAAP EPS Increases 23% To $3.91; Increases 2015 Standalone Forecast 2/18/2015 12:37:51 PM
Actavis (ACT) Confirms Temporary Injunction From Appeals Court Related To Generic Pulmicort RESPULES 2/18/2015 7:57:43 AM
Actavis (ACT) Touts Potential $6 Billion Pipeline at Investor Meeting 2/18/2015 6:50:23 AM
Actavis (ACT) to Officially Adopt Allergan (AGN) Name 2/18/2015 6:03:48 AM
Actavis (ACT) Launches The "Unconditional Love" Campaign To Recognize Alzheimer's Disease Caregivers 2/16/2015 11:35:58 AM
12345678910...